Next Article in Journal
Survey on Sternal Wound Management in the Italian Pediatric Cardiac Intensive Care Units
Next Article in Special Issue
Clinical Factors Associated with COVID-19 Severity in Mexican Patients: Cross-Sectional Analysis from a Multicentric Hospital Study
Previous Article in Journal / Special Issue
Socio-Demographic Factors Involved in a Low-Incidence Phase of SARS-CoV-2 Spread in Sicily, Italy
 
 
Article

Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly

by 1,* and 2,3
1
Doba Faculty, 2000 Maribor, Slovenia
2
Medical Faculty Ljubljana, University of Ljubljana, 1000 Ljubljana, Slovenia
3
General Hospital Jesenice, 4270 Jesenice, Slovenia
*
Author to whom correspondence should be addressed.
Academic Editor: Raphael B. Stricker
Healthcare 2021, 9(7), 868; https://doi.org/10.3390/healthcare9070868
Received: 17 June 2021 / Revised: 7 July 2021 / Accepted: 8 July 2021 / Published: 9 July 2021
The clinical validation of the NADAL COVID-19 antigen test (Nal von Minden, Moers, Germany) started in eight Slovenian long-term health care facilities in October 2020. The purpose of clinical validation is to implement the test into the everyday working process in long-term care (LTC) facilities and demonstrate how it can be used to mitigate the spread of the virus in these environments. The facilities compared the results of antigen tests to the results obtained using Cobas 6800 SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) (Roche, USA). Sensitivity (86.96%, 95% CI: 66.41–97.23%) and specificity (88.24%, 95% CI: 80.35–93.77%) of the NADAL COVID-19 antigen test were good. Rapid antigen testing served well for early detection of infection and helped to prevent and control spread of the SARS Cov2 in six out of eight LTCs. Moreover, mini-outbreaks were quickly resolved in all six LTCs. Locally validated immunochromatographic SARS-CoV-2 antigen testing can be used to contain the spread of the virus in LTCs. Antigen tests also deliver accurate information very quickly if used early with a low threshold. The NADAL COVID-19 antigen test proved to be a good screening tool to detect SARS-COV-2 in LTCs. View Full-Text
Keywords: immunochromatographic SARS-CoV-2 antigen test; clinical validation; POCT—point of care testing; long-term care immunochromatographic SARS-CoV-2 antigen test; clinical validation; POCT—point of care testing; long-term care
MDPI and ACS Style

Ifko, M.; Skvarc, M. Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly. Healthcare 2021, 9, 868. https://doi.org/10.3390/healthcare9070868

AMA Style

Ifko M, Skvarc M. Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly. Healthcare. 2021; 9(7):868. https://doi.org/10.3390/healthcare9070868

Chicago/Turabian Style

Ifko, Martina, and Miha Skvarc. 2021. "Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight Long-Term Care Facilities for the Elderly" Healthcare 9, no. 7: 868. https://doi.org/10.3390/healthcare9070868

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop